News MHRA gives Alnylam 'innovation passport' for hypertension dr... The UK medicines regulator has awarded Alnylam's RNAi-based therapy zilebesiran for hypertension an 'innovation passport', a
News MHRA grants bluebird 'innovation passport' for sickle cell t... bluebird bio's sickle cell disease (CD) gene therapy LentiGlobin is the latest recipient of an 'innovation passport' introduced in the UK earlier this year to speed up NHS access to promisi
News Chiesi signs $1.9bn deal to buy KalVista and its HAE drug Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.